2C-B: The Neuroscience

Most of the psychedelics driving the modern research renaissance are tryptamines — psilocybin, DMT, LSD’s lysergamide core. 2C-B belongs to the other great psychedelic family, the phenethylamines, the same structural lineage as mescaline. It was first synthesized in 1974 by Alexander Shulgin, the Berkeley chemist who spent decades systematically creating and self-testing psychoactive compounds, and it sits deliberately between the empathogen MDMA and the classic psychedelic LSD. To understand it, you have to hold its chemistry, its unusually steep dose–response, and its contaminated supply chain together at once. This article is education, not medical advice.

The molecule Shulgin was proudest of

2C-B opened the “2C” series — a set of 2,5-dimethoxy phenethylamines (2C-B, 2C-I, 2C-E, 2C-T-2, and dozens more) named for the two carbons between the benzene ring and the amine nitrogen. In his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), written with Ann Shulgin, he listed 2C-B among his “magical half-dozen” and called it one of his favorites; his wife recalled that he nicknamed it the “Great Teacher” (2C-B overview).

What makes 2C-B scientifically interesting is precisely what its users describe: it seems to occupy the territory between MDMA and LSD without being fully either. That in-between quality is not marketing folklore — it maps onto a real and somewhat unusual pharmacology, and onto a dose–response curve steep enough that Shulgin himself issued explicit warnings about it. Structurally, 2C-B is a simple bromination away from the mescaline lineage, and it is the parent scaffold from which the far more dangerous NBOMe compounds were later derived — a fact that turns out to matter enormously for its safety story.

A brief, strange commercial history

Before it was controlled, 2C-B had a short life as a legal product. In the 1980s and early 1990s it was manufactured and sold — including by the German firm Drittewelle under the trade name Erox, and in Dutch “smart shops” as Nexus — and marketed, dubiously, as an aphrodisiac claimed to help with libido and sexual function. Other street and brand names accumulated: Performax, Venus, Bromo, Toonies, Spectrum (DOJ/NDIC bulletin). A small number of psychotherapists had also explored it in the 1970s as an adjunct to therapy, sometimes as a gentler follow-up to MDMA.

Its rise as a recreational drug is inseparable from MDMA’s fall. After MDMA was placed in US Schedule I in 1985, 2C-B was taken up as a legal replacement on the club and rave scene, which is exactly what drew regulatory attention. The DEA emergency-scheduled it in 1994, and it was placed permanently in Schedule I effective June 5, 1995 (DEA scheduling ruling). Notably, the compound abandoned by 1970s therapists was reportedly set aside not for danger but for practical reasons — significant gastrointestinal effects and, in their view, a lack of MDMA-like empathogenic push.

Mechanism: serotonergic, and more contested than the textbooks suggest

If you had to name a single mechanistic family, it would be the serotonin 5-HT2 receptors. 2C-B binds the 5-HT2A receptor (the target shared by essentially all classic serotonergic psychedelics), the 5-HT2C receptor, and, with lower affinity, the 5-HT2B receptor. 5-HT2A engagement is the presumed engine of its perceptual and psychedelic effects; 5-HT2C activity plausibly shapes mood and appetite dimensions.

But the popular shorthand — “2C-B is a 5-HT2A partial agonist” — hides a genuine scientific disagreement worth stating plainly. Early functional studies described 2C-B as a low-efficacy partial agonist, and in at least one influential Xenopus oocyte study it behaved as a 5-HT2A antagonist, blocking serotonin’s effect rather than mimicking it (Villalobos et al., 2004). More recent binding and functional work has consistently reported higher efficacy — in one dataset near-full agonism at 5-HT2A, 5-HT2B, and 5-HT2C (Moya et al., 2007). The discrepancy likely reflects differences in cell systems, assays, and readouts rather than a settled biological fact. Flag: the precise intrinsic efficacy of 2C-B at 5-HT2A is not resolved. What can be said carefully is that its activity appears lower or more variable than that of full agonists like psilocin and LSD — a plausible partial explanation for why users describe it as more “clear-headed,” less “ego-threatening,” and more visual-than-cognitive than the classic tryptamines.

Beyond the 5-HT2 receptors, 2C-B touches the broader monoamine system at much weaker potency. It interacts with the serotonin transporter (SERT) — with inhibitory potency in the same rough range as MDMA in some assays, though at concentrations whose real-world relevance is uncertain — and has far weaker activity at the norepinephrine and dopamine transporters (Rickli et al., receptor profiles). Intriguingly, the 2026 imaging work (below) found that what most distinguished 2C-B’s brain signature from psilocybin’s tracked the dopamine transporter, a hint that its “secondary pharmacology” beyond 5-HT2A may actively shape the experience. As with any psychoactive drug, the honest summary is that one receptor leads but the felt effect is a chord.

The steep, biphasic dose–response

2C-B’s single most distinctive pharmacological feature is the shape of its dose–response curve. Shulgin repeatedly warned that it is unusually steep: over roughly the 12–24 mg oral range, “every 2 mg increment can result in a profound increase or change in effects.” The character of the experience shifts with dose, not just its intensity. Lower doses (commonly cited around 5–15 mg) lean toward MDMA-like stimulation, warmth, sociability, and heightened tactile, visual, and sexual sensation, with minimal hallucination. Higher doses (roughly 15–30 mg) bring the LSD-like end forward — geometric visuals, color enhancement, closed-eye imagery, time dilation, and altered consciousness. Higher doses are described as producing more intense but not necessarily longer effects.

This biphasic profile is why 2C-B is so often called a “candyflip in a single molecule” or a blend of MDMA and LSD. A controlled dose-ranging study captured the pattern quantitatively: on a subjective visual-analogue scale, peak “any drug effect” ratings rose from roughly 27 at 10 mg to 56 at 20 mg to 72 at 30 mg, while “bad drug effects” stayed minimal at low doses and climbed at higher ones — the same broad shape seen with LSD and psilocybin (Arikci et al., 2026). Threshold effects appear around 4 mg. The practical consequence of a steep curve is obvious and important: a small error in an already small dose can produce a disproportionately large change in experience.

Pharmacokinetics: oral, insufflated, and fast-cleared

2C-B is active orally and, less commonly, by insufflation. Orally, onset is roughly 0.5–1.2 hours, effects peak around 2.5 hours on average, and the total experience lasts about 4–6 hours (reported ranges span 2–8 hours) — generally shorter than psilocybin (Papaseit et al., 2018). Insufflated, doses are roughly one-third of oral doses, onset is faster and the peak more intense, and the experience is compressed; the nasal route is also widely reported as painful. Its measured elimination half-life is short, on the order of 1–2.5 hours, consistent with the relatively contained duration.

Metabolically, 2C-B is handled mainly by monoamine oxidase (both MAO-A and MAO-B) via deamination, with the cytochrome P450 system — including CYP2D6 — playing a secondary role; recent human plasma work suggests CYP2D6 can degrade it rapidly (Thomann et al., 2025). The dominant human metabolic routes are deamination and O-demethylation, yielding acid and alcohol metabolites that appear at far higher plasma concentrations than the parent drug (Carmo et al., 2005). The MAO dependence carries a direct safety implication: combining 2C-B with an MAO inhibitor (including certain antidepressants and the ayahuasca admixtures) is a plausible route to dangerous serotonergic drug interaction, because blocking MAO removes a primary clearance pathway.

Subjective and neuroscience effects: milder, clearer, more visual

Across anecdotal reports and the small formal literature, a consistent portrait emerges. 2C-B tends to be experienced as more visual and bodily than cognitive — Shulgin described “a luxury of sensory enhancement (visual, sexual, gustatory) with a minimum of introspective demands.” Users frequently call it “clear-headed,” non-ego-threatening, and easier to manage than LSD or psilocybin, which is the basis for its (double-edged) reputation as a “beginner” psychedelic. That reputation cuts both ways: it is also described as more of a party drug, with fewer of the challenging, emotional-breakthrough, or mystical-type experiences that appear to underlie psilocybin’s therapeutic signal.

The 2020s finally produced controlled human comparisons. A 2023 double-blind trial comparing 2C-B and psilocybin found that 2C-B produced fewer negative mood effects, more positive mood effects, and less intense alterations of consciousness — less oceanic boundlessness, ego dissolution, and time dilation — with equivalent effects on visual changes and body perception (2C-B vs psilocybin, Clin Pharmacol Ther 2023). The authors suggested 2C-B might, in principle, suit people who are afraid of the full psychedelic experience or at higher risk of a difficult one. A 2026 Basel dose-finding study (Arikci and colleagues) went further, comparing 2C-B directly against both MDMA and psilocybin in healthy volunteers precisely because its in-vitro profile straddles the two — early confirmation, in a rigorous design, of the “between MDMA and LSD/psilocybin” intuition (Arikci et al., Neuropsychopharmacology 2026).

On the imaging side, a 2026 study in Molecular Psychiatry (Mallaroni and colleagues, Maastricht) used 7-Tesla resting-state fMRI in a placebo-controlled crossover to compare 20 mg 2C-B with 15 mg psilocybin. Both drugs reshaped brain organization in broadly similar ways — reducing within-network connectivity in default-mode and visual networks, increasing communication between networks, and raising measures of neural complexity/entropy — the now-familiar psychedelic signature of a more globally integrated, less modular brain. But 2C-B’s effects were less extensive: it produced smaller between-network integration and less pronounced dampening of dynamic connectivity fluctuations than psilocybin, alongside a distinctive dopaminergic-linked signature (Mallaroni et al., Mol Psychiatry 2026). The neuroscience, in other words, echoes the phenomenology: recognizably psychedelic, but lighter-touch.

Clinical and research status: thin, honest, and only now moving

For most of its fifty-year history, 2C-B was scarcely studied in humans — a Schedule I compound of interest mainly to forensic toxicologists and harm-reduction services. Even sympathetic reviewers noted that “very little scientific research” existed (Dean et al., 2013). The recent controlled Basel and Maastricht studies are genuinely new, but they are small, single-site, exploratory, and focused on healthy volunteers and mechanism — not clinical efficacy. There are no completed trials of 2C-B as a treatment for any condition, no established therapeutic protocol, and no regulatory approval anywhere. Its therapeutic potential is, at most, a hypothesis that researchers have only just begun to test — and the reasons it stayed under-studied (Schedule I status, its reputation as a recreational rather than “serious” psychedelic, and the historical dominance of psilocybin and MDMA in the research pipeline) are practical and political as much as scientific.

Safety and harm reduction, held honestly

An evidence-forward account has to be precise here, because 2C-B’s risk profile is genuinely mixed. On one hand, no death has been attributed to 2C-B alone in the published literature (as of the most recent reviews), only a small number of intoxication case reports, and Shulgin recorded an accidental 100 mg ingestion — several times a strong dose — without lasting harm. On the other hand, the drug is not benign: at doses above roughly 20–30 mg, frightening hallucinations, tachycardia, hypertension, and hyperthermia can occur, and rare but severe case reports describe serotonin syndrome, seizures, brain edema, persistent psychosis, and acquired synesthesia following high or unknown doses (Spoelder et al., 2019; Huang & Bai, 2011). Its safety window is generally thought to be narrower than LSD’s or psilocybin’s, closer to mescaline’s.

Two hazards deserve special emphasis. The first is misidentification and substitution — the single most important harm-reduction fact about 2C-B. Because 2C-B is the chemical parent of the NBOMe series (25B-NBOMe and relatives), and because those compounds are cheap, extraordinarily potent, and active in microgram amounts, powders and blotters sold as “2C-B” have repeatedly turned out to be NBOMes or other adulterants instead (Poulie et al., DARK Classics: NBOMes 2020; drug alert: “2C-B” that was 25C-NBOMe). NBOMes have a punishing dose-response and have caused agitation, hyperthermia, seizures, hospitalizations, and deaths — including documented cases of people who died believing they had taken a milder drug (DEA NBOMe fact sheet). This is why drug-checking and reagent testing are so consequential for anything sold as 2C-B: the molecule’s own risk is moderate, but its market is contaminated. The second hazard is serotonergic interaction: combining 2C-B with MAO inhibitors, SSRIs, other stimulants, or additional psychedelics raises the risk of serotonin toxicity, and its 5-HT2B activity raises a theoretical (unproven) concern about cardiac valve effects with heavy chronic use — the same concern flagged for other 5-HT2B-active drugs.

The honest bottom line

2C-B is a compound built on a paradox its own chemist appreciated. Its pharmacology places it deliberately between the empathogen and the classic psychedelic, and both the new controlled trials and the new imaging data support that in-between identity: recognizably psychedelic in the brain, but milder, clearer, and shorter than psilocybin, with a dopaminergic accent that may set it apart. It is also a drug whose steep dose–response punishes carelessness, whose evidence base is only now emerging from a fifty-year gap, and whose most serious real-world danger is not what the molecule does but what gets sold under its name. Holding all of that together — a genuinely interesting neuroscience, a thin but growing clinical literature, a moderate direct-risk profile, and a contaminated supply — is the only accurate way to think about Shulgin’s “Great Teacher.”

OOTW Journal is educational and does not provide medical advice. 2C-B is a Schedule I controlled substance in the US with no approved medical use; its therapeutic potential is confined to early research. Substances sold as “2C-B” are frequently misidentified. If you or someone you know experiences agitation, high fever, rigidity, seizures, or confusion after taking a psychedelic, seek emergency care. This article is education, not medical advice.